Sector News

Roche to pay up to $489 mln for next-generation antibody developer

December 22, 2014
Life sciences
(Reuters) – Roche has agreed to pay up to $489 million to acquire Austrian biotech company Dutalys, a specialist in the discovery and development of so-called bi-specific antibodies, the Swiss drugmaker said on Thursday.
 
Bi-specific antibody therapy is a fast-emerging technology that could prove more potent than conventional antibodies, which have become mainstay treatments for an array of cancers.
 
Roche will make an upfront cash payment of $133.75 million to shareholders in the Vienna-based company and make additional payments of up to $355 million if certain predetermined milestones are reached.
 
Dutalys has developed a proprietary technology, known as DutaMab, but its programmes are still at an early stage in the drug development process. Roche said the bi-specific antibodies produced with this platform could provide novel molecules for several therapeutic areas, though it gave no details.
 
The deal strengthens Roche’s leading position in the development of therapeutic antibodies, an area in which it already boasts several multibillion-dollar-a-year sellers, including Avastin and Herceptin for cancer.
 
Bi-specific antibodies are artificial proteins composed of fragments of two different monoclonal antibodies, which can bind in two different places in a disease pathway. Roche believes that the DutaMab technology, which creates fully human bi-specific antibodies, promises particularly good binding and stability.
 
Privately owned Dutalys was founded in April 2010. It is supported by seed financing from Austria Wirtschaftsservice, research grants from the Austrian Research Promotion Agency and the Technology Agency of the City of Vienna as well as funding from the Austrian Academic Business Incubator.
 
(Reporting by Ben Hirschler; Editing by David Goodman)

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend